Helius Medical Technologies (HSDT) AI Stock Analysis

• Market Cap: $117.09M
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: 87.45%
• EPS Growth: 72.30%
• Country: US
• Employees: 21
• Sector: Financial
• Sector Strength: 70
• Industry: Medical - Devices
• EPS (TTM): -32.89
• Shares Outstanding: 41,301,400
• 10 Day Avg. Volume: 1,311,391
• 30 Day Avg. Volume: 1,547,142
• PEG Ratio: 2.86
• Price to Book (P/B): 1.29K
• Price to Sales (P/S): 2618.59
• P/FCF Ratio: -123.27
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: -5.27
• Enterprise Value/Gross Profit: -10.61
• Enterprise Value/Ebitda: 0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $2.50 ▼(-22.12% Downside)

The score is primarily constrained by weak financial fundamentals: very large losses, ongoing cash burn, and negative equity outweigh the recent revenue rebound and low debt. Technicals also remain bearish with the stock trading below major moving averages and negative MACD. Earnings-call positives around fundraising and staking execution modestly support the score but do not offset the scale of losses.

Positive Factors

Innovative Product Development

The company's focus on innovative therapies for neurological diseases positions it well in a niche market with growing demand for non-invasive treatments.

Strategic Partnerships

Partnerships with insurance companies can enhance market access and adoption of Helius' products, supporting long-term revenue growth.

FDA Submission for PoNS Device

FDA approval for the PoNS device could significantly expand its market, improving patient outcomes and boosting the company's competitive position.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market penetration and sales growth, which may impact the company's ability to scale its operations.

Negative Free Cash Flow

Negative free cash flow suggests cash generation issues, potentially limiting the company's ability to invest in growth opportunities or manage debt.

Significant Net Loss

Substantial net losses highlight financial instability and may hinder the company's ability to sustain operations without additional funding.

Helius Medical Technologies Business Overview & Revenue Model

Company Description

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

How the Company Makes Money

Helius Medical Technologies generates revenue primarily through the sale of its medical devices, specifically its portable neuromodulation device (PND), which is utilized in clinical settings and by patients at home. The company may also engage in partnerships with healthcare providers and institutions to facilitate the distribution of its products, thereby expanding its market reach. Additionally, HSDT may explore revenue streams through reimbursement agreements with insurance companies, allowing patients to access their technology with financial support. The ongoing development of new applications for its technology and potential collaborations with pharmaceutical companies further contribute to its revenue potential.

Helius Medical Technologies Financial Statement Overview

Summary

Helius Medical Technologies is facing significant financial challenges with declining revenue and profitability. The company has been operating at a loss for several years, affecting both cash flow and equity. While leverage remains low, the overall financial health is strained by negative earnings and cash flow. The company must focus on improving operational efficiency and revenue growth to enhance financial stability.

Income Statement

Helius Medical Technologies has shown declining revenue over recent years with a significant drop from $644,000 in 2023 to $520,000 in 2024. The company reports consistent net losses, with a net profit margin of -2257.69% in 2024. The EBIT and EBITDA margins are both negative, indicating operational difficulties. Revenue growth is negative, further reflecting the challenging business environment.

Balance Sheet

The company's balance sheet reveals a highly leveraged position with a debt-to-equity ratio of 0.01 in 2024, indicating minimal use of debt financing. However, stockholders' equity has decreased over time, reducing financial strength. The equity ratio is 29.89%, suggesting a moderate reliance on equity financing. Return on equity is negative due to consistent net losses.

Cash Flow

The cash flow statement indicates negative free cash flow of -$11,046,000 in 2024, signaling cash flow challenges. The operating cash flow to net income ratio is negative, reflecting poor cash generation from operations compared to net losses. Despite some financing cash inflows, the company struggles with cash outflows, impacting its liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	941.00K	520.00K	644.00K	787.00K	522.00K	661.00K
Gross Profit	467.00K	-62.00K	61.00K	324.00K	224.00K	-90.00K
EBITDA	-368.40M	-13.80M	-12.11M	-14.50M	-17.82M	-13.65M
Net Income	-370.37M	-11.74M	-8.85M	-14.07M	-18.13M	-14.13M
Balance Sheet
Total Assets	475.92M	3.54M	7.69M	17.29M	14.10M	6.55M
Cash, Cash Equivalents and Short-Term Investments	124.05M	1.09M	5.18M	14.55M	11.01M	3.33M
Total Debt	0.00	12.00K	57.00K	110.00K	3.00K	91.00K
Total Liabilities	628.31M	2.48M	5.34M	9.14M	2.85M	2.68M
Stockholders Equity	-152.39M	1.06M	2.35M	8.15M	11.26M	3.87M
Cash Flow
Free Cash Flow	-12.71M	-11.05M	-10.45M	-14.33M	-13.44M	-11.80M
Operating Cash Flow	-12.71M	-11.04M	-10.42M	-14.31M	-13.39M	-11.74M
Investing Cash Flow	-267.38M	-5.00K	-29.00K	-11.00K	-56.00K	-9.00K
Financing Cash Flow	400.68M	6.95M	1.08M	17.87M	21.13M	9.64M

Helius Medical Technologies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSDT, the sentiment is Neutral. The current price of 3.21 is above the 20-day moving average (MA) of 3.01, below the 50-day MA of 3.85, and below the 200-day MA of 61.63, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 41.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HSDT.

Helius Medical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	72 Outperform	$275.25M	22.08	10.53%	―	18.90%	29.22%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
CVRX	48 Neutral	$212.56M	-3.62	-91.88%	―	18.44%	25.42%
SGHT	48 Neutral	$379.62M	-8.27	-57.91%	―	-4.39%	11.70%
OM	45 Neutral	$82.68M	-0.43	-92.33%	―	4.65%	68.71%
HSDT	43 Neutral	$117.09M	>-0.01	―	―	87.45%	72.30%
SNWV	42 Neutral	$265.69M	-17.41	―	―	40.89%	-749.65%

Helius Medical Technologies Corporate Events

Solana Company Releases Corporate Presentation and Report

On November 3, 2025, Solana Company, previously known as Helius Medical Technologies, shared a corporate presentation and a press release on their website. These documents, which are part of a Current Report, include forward-looking statements and are intended for informational purposes only, highlighting potential risks and uncertainties associated with the company’s future operations and financial projections.

The most recent analyst rating on (HSDT) stock is a Sell with a $6.50 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Technologies Elects New Director, Approves Proposals

On October 30, 2025, Solana Company held a special meeting where stockholders elected a new director and approved several proposals, including the issuance of shares related to strategic advisor warrants and cryptocurrency transactions. These decisions reflect the company’s strategic financial maneuvers to enhance its market position and operational capabilities, potentially impacting stakeholders by expanding its equity base and embracing cryptocurrency as part of its financial strategy.

The most recent analyst rating on (HSDT) stock is a Sell with a $6.50 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Technologies Reports Strong Staking Performance

On October 29, 2025, Solana Company announced an update on its SOL token holdings and staking performance, revealing an increase of 0.1 million SOL since October 6, 2025, bringing its total to over 2.3 million SOL. The company reported an average gross staking yield of 7.03% APY for October, outperforming the top 10 validators’ average by 36 basis points, highlighting its effective digital asset strategy and strong market positioning.

The most recent analyst rating on (HSDT) stock is a Sell with a $6.50 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical: Strategic Share Resale Amid Market Volatility

On October 20, 2025, Solana Company announced its decision to proceed with the scheduled registration for resale of shares purchased in a recent private placement, despite market volatility. This strategic move is intended to establish a foundation of committed long-term shareholders and position the company as a strong investment option for institutional investors. Solana Company aims to differentiate itself by actively accumulating Solana per share and leveraging capital markets to acquire additional Solana, with a focus on maximizing shareholder value and contributing to the growth of the Solana ecosystem.

The most recent analyst rating on (HSDT) stock is a Sell with a $9.50 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.